Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB015 vs Cosentyx PK/Safety Study in Healthy Chinese Males
NCT05734482Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of secukinumab in psoriasis (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-time Curve From Zero Hours Extrapolated to Infinite Time up to 2688 hours and Maximum Concentration of Secukinumab up to 2688 hours. Started Feb 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05734482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734482.